Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

Although an expanding array of effective treatments has resulted in recent improvement in survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification of prognostic factors remains a priority. We assessed the prognostic impact of time to progression of dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Bond, David A., Switchenko, Jeffrey M., Villa, Diego, Maddocks, Kami, Churnetski, Michael, Gerrie, Alina S., Goyal, Subir, Shanmugasundaram, Krithika, Calzada, Oscar, Kolla, Bhaskar, Bachanova, Veronika, Gerson, James N., Barta, Stefan K., Hill, Brian T., Sawalha, Yazeed, Martin, Peter, Maldonado, Edward, Gordon, Max, Danilov, Alexey V., Grover, Natalie S., Mathews, Stephanie, Burkart, Madelyn, Karmali, Reem, Ghosh, Nilanjan, Park, Steven I., Epperla, Narendranath, Badar, Talha, Guo, Jin, Hamadani, Mehdi, Fenske, Timothy S., Malecek, Mary-Kate, Kahl, Brad S., Flowers, Christopher R., Blum, Kristie A., Cohen, Jonathon B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153047/
https://www.ncbi.nlm.nih.gov/pubmed/34516611
http://dx.doi.org/10.1182/bloodadvances.2021004765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153047/
https://www.ncbi.nlm.nih.gov/pubmed/34516611
http://dx.doi.org/10.1182/bloodadvances.2021004765

Ejemplares similares